RedHill Biopharma Reports 2016 Fourth Quarter and Full-Year Financial Results

• RedHill maintains a strong and debt-free balance sheet with approximately $66 million in cash and cash equivalents at the end of 2016, allowing the Company to continue to execute its development and U.S. commercialization plans

Select 2016 milestones include:

• Successful final results from the first Phase III study with RHB-105 for the treatment of H. pylori infection 
• Positive and unanimous independent DSMB recommendation for the continuation of the Phase III study with RHB-104 for Crohn’s disease (the MAP US study)
• Encouraging top-line final results from the Phase IIa proof-of-concept study with RHB-104 for relapsing-remitting multiple sclerosis
• Exclusive U.S. co-promotion agreement with Concordia for gastrointestinal drug Donnatal^®

Select potential milestones expected in 2017:  

• Initiation of a confirmatory Phase III study with RHB-105 for the treatment of H. pylori infection, expected in Q2/2017
• Second independent DSMB meeting for the MAP US Phase III study with RHB-104 for Crohn’s disease, including an interim efficacy analysis and an evaluation of an option for early stop for success for overwhelming efficacy, expected in Q2/2017
• Top-line results from the BEKINDA^® Phase III study for gastroenteritis (the GUARD study), expected in Q2/2017 
• Top-line results from the BEKINDA^® Phase II study for IBS-D, expected mid-2017 
• Initiation of promotional activities for Donnatal® in selected U.S. territories  

TEL-AVIV, Israel, Feb 24 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today reported its financial results for the fourth quarter and full-year ended December 31, 2016.

SOURCE : RedHill Biopharma Ltd.